Antiviral agents are urgently needed to fight severe acute respiratory syndrome (SARS). We showed that niclosamide, an existing antihelminthic drug, was able to inhibit replication of a newly discovered coronavirus, SARS-CoV; viral antigen synthesis was totally abolished at a niclosamide concentration of 1.56 microM, as revealed by immunoblot analysis. Thus, niclosamide represents a promising drug candidate for the effective treatment of SARS-CoV infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC434198 | PMC |
| http://dx.doi.org/10.1128/AAC.48.7.2693-2696.2004 | DOI Listing |
Publication Analysis
Top Keywords
severe acute
8
acute respiratory
8
respiratory syndrome
8
inhibition severe
4
syndrome coronavirus
4
coronavirus replication
4
niclosamide
4
replication niclosamide
4
niclosamide antiviral
4
antiviral agents
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!